Campbell & CO Investment Adviser LLC Lowers Stake in Axsome Therapeutics, Inc. $AXSM

Campbell & CO Investment Adviser LLC cut its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 34.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,077 shares of the company’s stock after selling 3,177 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Axsome Therapeutics were worth $738,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc grew its holdings in Axsome Therapeutics by 20,300.0% in the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after purchasing an additional 203 shares during the period. First Horizon Corp acquired a new position in shares of Axsome Therapeutics during the 3rd quarter worth approximately $34,000. Ameritas Advisory Services LLC purchased a new position in shares of Axsome Therapeutics during the 2nd quarter valued at approximately $77,000. Wilmington Savings Fund Society FSB grew its stake in Axsome Therapeutics by 4,375.0% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 716 shares of the company’s stock valued at $87,000 after acquiring an additional 700 shares during the period. Finally, Assetmark Inc. grew its stake in Axsome Therapeutics by 13.9% in the 2nd quarter. Assetmark Inc. now owns 1,124 shares of the company’s stock valued at $117,000 after acquiring an additional 137 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock opened at $184.50 on Wednesday. The business’s 50 day moving average price is $156.51 and its 200 day moving average price is $131.77. The company has a market cap of $9.30 billion, a price-to-earnings ratio of -39.51, a PEG ratio of 9.74 and a beta of 0.44. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. Axsome Therapeutics, Inc. has a one year low of $86.99 and a one year high of $185.98.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. The business’s quarterly revenue was up 63.2% on a year-over-year basis. On average, research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on AXSM shares. Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Oppenheimer reiterated an “outperform” rating and issued a $220.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, December 31st. HC Wainwright boosted their price objective on Axsome Therapeutics from $200.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday. Robert W. Baird set a $209.00 target price on Axsome Therapeutics in a research report on Tuesday, January 13th. Finally, Mizuho set a $217.00 price target on Axsome Therapeutics in a research note on Wednesday, December 31st. Nineteen research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $202.00.

Insider Activity

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $170.38, for a total transaction of $5,326,249.18. Following the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,231,677.02. The trade was a 81.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark E. Saad sold 37,577 shares of the business’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the completion of the transaction, the director owned 10,002 shares in the company, valued at $1,652,130.36. The trade was a 78.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 420,903 shares of company stock valued at $63,552,838. 22.40% of the stock is owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.